At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 04-24 13:42:55 EDT
346.50
-2.12
-0.61%
High347.66Low342.53Vol1.04M
Open346.00D1 Closing348.62Amplitude1.47%
Mkt Cap186.58BTradable Cap186.07BTotal Shares538.48M
T/O360.23MT/O Rate0.19%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Amgen this quarter’s revenue is expected to increase by 6.60%, and institutional views are predominantly bullish
Earnings Agent  ·  04-24 01:08
Earning Preview: Amgen this quarter’s revenue is expected to increase by 6.60%, and institutional views are predominantly bullish
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Medpace Holdings (MEDP) and Ultragenyx Pharmaceutical (RARE)
TIPRANKS  ·  04-24 19:00
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Medpace Holdings (MEDP) and Ultragenyx Pharmaceutical (RARE)
Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
TIPRANKS  ·  04-24 00:31
Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
Amgen Announces CTO Retirement and Strategic Leadership Realignment
TIPRANKS  ·  04-23 04:51
Amgen Announces CTO Retirement and Strategic Leadership Realignment
Amgen names Sean Bruich chief technology officer as David Reese retires
Reuters  ·  04-23 04:00
Amgen names Sean Bruich chief technology officer as David Reese retires
Amgen Announces Retirement of David M. Reese, Executive Vice President and Chief Technology Officer
THOMSON REUTERS  ·  04-23 04:00
Amgen Announces Retirement of David M. Reese, Executive Vice President and Chief Technology Officer
Press Release: AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
Dow Jones  ·  04-23 04:00
Press Release: AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
The next time your health insurance denies a medication or procedure, here's how to appeal it. You'll probably win.
Dow Jones  ·  04-23 02:40
The next time your health insurance denies a medication or procedure, here's how to appeal it. You'll probably win.
Amgen (AMGN) Initiated with a Hold at Canaccord Genuity
TIPRANKS  ·  04-22 16:53
Amgen (AMGN) Initiated with a Hold at Canaccord Genuity
Amgen Initiated at Hold by Canaccord Genuity
Dow Jones  ·  04-21
Amgen Initiated at Hold by Canaccord Genuity
Amgen (AMGN) Receives a Hold from Bernstein
TIPRANKS  ·  04-21
Amgen (AMGN) Receives a Hold from Bernstein
Canaccord Genuity Initiates Amgen at Hold With $366 Price Target
MT Newswires Live  ·  04-21
Canaccord Genuity Initiates Amgen at Hold With $366 Price Target
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Brookdale Senior Living (BKD) and 10x Genomics (TXG)
TIPRANKS  ·  04-21
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Brookdale Senior Living (BKD) and 10x Genomics (TXG)
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  04-21
Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day
Amgen initiated with a Hold at Canaccord
TIPRANKS  ·  04-21
Amgen initiated with a Hold at Canaccord
Market Chatter: Pfizer, Amgen Eyeing Hong Kong Expansion
MT Newswires Live  ·  04-20
Market Chatter: Pfizer, Amgen Eyeing Hong Kong Expansion
Will Amgen’s Subcutaneous Tepezza Success Reshape Viridian Therapeutics' (VRDN) Thyroid Eye Disease Narrative?
Simply Wall St.  ·  04-19
Will Amgen’s Subcutaneous Tepezza Success Reshape Viridian Therapeutics' (VRDN) Thyroid Eye Disease Narrative?
Is It Too Late To Consider Amgen (AMGN) After A 32% One-Year Share Price Rally?
Simply Wall St.  ·  04-19
Is It Too Late To Consider Amgen (AMGN) After A 32% One-Year Share Price Rally?
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  04-18
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?
TradingKey  ·  04-17
GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--